NEW YORK, March 14 - Oxford GlycoSciences and BioInvent International on Thursday said they are partnering for three years to identify, develop, manufacture, and commercialize therapeutic antibodies.
Terms of the agreement call for OGS to provide at least five target antigens per year, which it will identify and validate through its proteomics process. BioInvent, in turn, will apply its n-CoDeR phage display library to identify antibodies targeted to those antigens.
The companies will then select candidates to develop into therapeutic candidates, and BioInvent will manufacture all of the requisite pre-clinical and clinical materials.
Financial details of the deal were not disclosed. However, OGS said it will contribute research funding and will pay a technology access fee to BioInvent. Additionally, any antibody candidates that come out of the deal will be developed either jointly, in which case the costs of research and development and subsequent revenues will be equally split, or by OGS alone.
The terms also said that BioInvent will be able to select at least one antibody candidate each year. OGS, on the other hand, will be responsible to research and develop all other candidates, for which BioInvent will receive undisclosed milestone and royalty payments. However, OGS will retain all commercial rights for these solely developed products.